Bioventix PLC

LSE BVXP.L

Bioventix PLC Free Cash Flow Yield on January 14, 2025: 5.09%

Bioventix PLC Free Cash Flow Yield is 5.09% on January 14, 2025, a 50.71% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Bioventix PLC 52-week high Free Cash Flow Yield is 6.22% on December 20, 2024, which is 22.20% above the current Free Cash Flow Yield.
Bioventix PLC 52-week low Free Cash Flow Yield is 2.96% on February 21, 2024, which is -41.90% below the current Free Cash Flow Yield.
Bioventix PLC average Free Cash Flow Yield for the last 52 weeks is 3.77%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

LSE: BVXP.L

Bioventix PLC

CEO	Mr. Peter John Harrison MA
IPO Date	April 29, 2014
Location	United Kingdom
Headquarters	27–28 Eastcastle Street
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.

Key trends

Past 5 years